Search

Your search keyword '"Juengpanich, Sarun"' showing total 31 results
Start Over Author "Juengpanich, Sarun" Search Limiters Available in Library Collection
31 results on '"Juengpanich, Sarun"'

7. Risk factors and consequences of conversion in minimally invasive distal pancreatectomy

Author

Zhiyu Jiang, Long Pan, Mingyu Chen, Bin Zhang, Juengpanich Sarun, Sandra Fan, and Xiujun Cai

Subjects
conversion, minimally invasive distal pancreatectomy, open distal pancreatectomy, post-operative outcomes, retrospective study, risk factors, Surgery, RD1-811, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background: Although recent studies have reported potential benefits of laparoscopic approach in distal pancreatectomy, reports of conversion during minimally invasive distal pancreatectomy (MIDP) were limited. Methods: This was a retrospective study using data from Sir Run Run Shaw Hospital around May 2013 to December 2018. Outcomes of patients who had conversions during MIDP were compared with patients with successful MIDP and with patients undergoing open distal pancreatectomy (ODP). Results: Two-hundred and eighty-three cases were included in this study: 225 (79.5%) had MIDP, 30 (10.6%) had conversions and 28 (9.9%) had outpatient department. The risk factors for conversion included large lesion size (heart rates [HR]: 5.632, 95% confidencevinterval [CI]: 1.036–1.450, P = 0.018) and pancreatic cancer (HR: 6.957, 95% CI: 1.359–8.022, P = 0.009). Compared with MIDP, those who required conversion were associated with longer operations (P = 0.003), higher blood loss (P < 0.001) and more severe of the complications (P < 0.001). However, no statistically significant differences were found between the conversion group and ODP. Conclusions: Large lesion size and pancreatic cancer were reported to be independent risk factors for conversion during MIDP. As for post-operative outcomes, the outcomes of successfully MIDP were better than those for conversion. However, conversion did not lead to worsening outcomes when compared with ODP.

Published
2022
Full Text
View/download PDF

20. Bortezomib‐Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy

Author

Chen, Mingyu, primary, Juengpanich, Sarun, additional, Li, Shijie, additional, Topatana, Win, additional, Lu, Ziyi, additional, Zheng, Qiang, additional, Cao, Jiasheng, additional, Hu, Jiahao, additional, Chan, Esther, additional, Hou, Lidan, additional, Chen, Jiang, additional, Chen, Fang, additional, Liu, Yu, additional, Jiansirisomboon, Sukanda, additional, Gu, Zhen, additional, Tongpeng, Suparat, additional, and Cai, Xiujun, additional

Published
2022
Full Text
View/download PDF

25. Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data

Author

Zhen, Shi-hui, primary, Cheng, Ming, additional, Tao, Yu-bo, additional, Wang, Yi-fan, additional, Juengpanich, Sarun, additional, Jiang, Zhi-yu, additional, Jiang, Yan-kai, additional, Yan, Yu-yu, additional, Lu, Wei, additional, Lue, Jie-min, additional, Qian, Jia-hong, additional, Wu, Zhong-yu, additional, Sun, Ji-hong, additional, Lin, Hai, additional, and Cai, Xiu-jun, additional

Published
2020
Full Text
View/download PDF

31. Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma.

Author

Chen, Mingyu, Cao, Jiasheng, Hu, Jiahao, Topatana, Win, Li, Shijie, Juengpanich, Sarun, Lin, Jian, Tong, Chenhao, Shen, Jiliang, Zhang, Bin, Wu, Jennifer, Pocha, Christine, Kudo, Masatoshi, Amedei, Amedeo, Trevisani, Franco, Sung, Pil Soo, Zaydfudim, Victor M., Kanda, Tatsuo, and Cai, Xiujun

Subjects
RADIOMICS, CHEMOEMBOLIZATION, HEPATOCELLULAR carcinoma, CANCER treatment, THERAPEUTIC embolization
Abstract

Background: The preoperative selection of patients with intermediate-stage hepatocellular carcinoma (HCC) who are likely to have an objective response to first transarterial chemoembolization (TACE) remains challenging. Objective: To develop and validate a clinical-radiomic model (CR model) for preoperatively predicting treatment response to first TACE in patients with intermediate-stage HCC. Methods: A total of 595 patients with intermediate-stage HCC were included in this retrospective study. A tumoral and peritumoral (10 mm) radiomic signature (TPR-signature) was constructed based on 3,404 radiomic features from 4 regions of interest. A predictive CR model based on TPR-signature and clinical factors was developed using multivariate logistic regression. Calibration curves and area under the receiver operating characteristic curves (AUCs) were used to evaluate the model's performance. Results: The final CR model consisted of 5 independent predictors, including TPR-signature (p < 0.001), AFP (p = 0.004), Barcelona Clinic Liver Cancer System Stage B (BCLC B) subclassification (p = 0.01), tumor location (p = 0.039), and arterial hyperenhancement (p = 0.050). The internal and external validation results demonstrated the high-performance level of this model, with internal and external AUCs of 0.94 and 0.90, respectively. In addition, the predicted objective response via the CR model was associated with improved survival in the external validation cohort (hazard ratio: 2.43; 95% confidence interval: 1.60–3.69; p < 0.001). The predicted treatment response also allowed for significant discrimination between the Kaplan-Meier curves of each BCLC B subclassification. Conclusions: The CR model had an excellent performance in predicting the first TACE response in patients with intermediate-stage HCC and could provide a robust predictive tool to assist with the selection of patients for TACE. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results